Navigation Links
UT Knoxville research may lead to better flu vaccine
Date:2/27/2008

KNOXVILLE -- New research from a scientist at the University of Tennessee, Knoxville, has uncovered information that may someday lead to a better flu vaccine.

While the research is an early step toward a better vaccine, the findings from Mark Sangster, a professor of microbiology, track a little-understood immune system cell's response to an influenza infection and reveal new information about where it is most concentrated in the body.

By analyzing the formation of the cells, known as memory B cells, Sangster and his colleagues may better understand how to stimulate their production by vaccination.

"When we see how these cells are formed in response to a full-on infection of the flu, we get a picture of the gold standard of the immune response and protection," said Sangster, who co-authored the paper with graduate student Hye Mee Joo and postdoctoral researcher Yuxia He.

At the heart of the research, said Sangster, was learning where memory B cells reside after an infection of the flu, and how many are in each location. The cells are created when the immune system responds to infection, and act as a sort of "first responder," specially tailored to the specific type of virus that triggered their creation.

When the body is faced with the flu again, these cells quickly begin making antibodies that fight the flu virus.

"By knowing where these cells reside after an infection, we can learn what this means in how they may respond to subsequent exposure to the virus," said Sangster. "It gives us a standard that we can use to evaluate and tailor how the body responds to vaccines."

One finding that surprised Sangster was that the memory B cells were found in especially high concentrations in the lungs -- organs not usually associated with an immune response.

"What we found is that the lungs are a complex and potentially very useful reservoir of immunological memory," he said.

B memory cells are much less understood than their immunological cousins known as T cells. According to Sangster, technological developments have made it easier to study T cells, leaving B cell discoveries slower in coming.

The findings, published in this week's online version of the Proceedings of the National Academy of Sciences, lay important groundwork for future flu vaccine research, said Sangster.

Since vaccines use either weakened or dead copies of the flu virus to trigger the body's immune system into responding, the body's response to the virus in the vaccine is different and less powerful than its response to a full-on infection.

"With this understanding of memory B cell formation in response to a full-on infection, we have a model for vaccines in the response that they generate," Sangster said.

He said one of the next steps will be to look at any differences in how memory B cells are formed by vaccines given by injection versus those inhaled through the nose. He noted that those differences may provide more clues about the significance of the pool of memory B cells in the lungs.

"The Holy Grail for all of this is to develop a vaccine that will protect against a wide range of subtypes and strains of the flu virus," said Sangster. "We're not there yet, but this knowledge is a step in that direction."


'/>"/>
Contact: Jay Mayfield
jay.mayfield@tennessee.edu
865-974-9409
University of Tennessee at Knoxville
Source:Eurekalert

Related medicine news :

1. Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again
2. This is your brain on jazz: researchers use MRI to study spontaneity, creativity
3. New research indicates that a common heart drug
4. First look: Princeton researchers peek into deepest recesses of human brain
5. Scripps research scientists devise approach that stops HIV at earliest stage of infection
6. Research May Yield New Weapons Against Sepsis
7. U of Minn researchers find primary alcohol prevention programs are needed for tweens
8. Researchers collaborate to find new vaccine technology decreases E. coli in beef cattle
9. Jan Marini Skin Research Introduces Age Intervention(R) Transitions - a New Frontier in Skin Care
10. Efforts to Recruit, Retain and Research Nations Social Workers Gain Bipartisan Support in Congress
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: